Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa by Reddi, Anand et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Pediatrics
Open Access Research article
Preliminary outcomes of a paediatric highly active antiretroviral 
therapy cohort from KwaZulu-Natal, South Africa
Anand Reddi*†1, Sarah C Leeper*†2, Anneke C Grobler3, Rosemary Geddes4, 
K Holly France1, Gillian L Dorse1, Willem J Vlok1, Mbali Mntambo1, 
Monty Thomas1, Kristy Nixon1, Helga L Holst1, Quarraisha Abdool Karim3, 
Nigel C Rollins5, Hoosen M Coovadia6 and Janet Giddy1
Address: 1Sinikithemba HIV/AIDS Clinic, McCord Hospital, Durban, South Africa, 2Children's Rights Centre, Durban, South Africa, 3CAPRISA, 
Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, 4Department of Community Health, Nelson R. 
Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, 5Department of Paediatrics and Child Health, Nelson R. 
Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa and 6Doris Duke Medical Research Institute, Nelson R. Mandela 
School of Medicine, University of KwaZulu-Natal, Durban, South Africa
Email: Anand Reddi* - areddi@fulbrightweb.org; Sarah C Leeper* - sarah.leeper@alumni.duke.edu; Anneke C Grobler - Grobler@ukzn.ac.za; 
Rosemary Geddes - geddes@ukzn.ac.za; K Holly France - holly@ptnmeth.org.za; Gillian L Dorse - gill@antinomy.co.za; 
Willem J Vlok - willem.vlok@gmail.com; Mbali Mntambo - mbalidlamuka@webmail.co.za; Monty Thomas - simbenlia@gmx.net; 
Kristy Nixon - kristy@mccord.co.za; Helga L Holst - holst@mccord.co.za; Quarraisha Abdool Karim - Abdoolq2@ukzn.ac.za; 
Nigel C Rollins - rollins@ukzn.ac.za; Hoosen M Coovadia - coovadiah@ukzn.ac.za; Janet Giddy - jgiddy@hebron.za.net
* Corresponding authors    †Equal contributors
Abstract
Background: Few studies address the use of paediatric highly active antiretroviral therapy (HAART) in Africa.
Methods: We performed a retrospective cohort study to investigate preliminary outcomes of all children eligible for
HAART at Sinikithemba HIV/AIDS clinic in KwaZulu-Natal, South Africa. Immunologic, virologic, clinical, mortality,
primary caregiver, and psychosocial variables were collected and analyzed.
Results: From August 31, 2003 until October 31, 2005, 151 children initiated HAART. The median age at HAART
initiation was 5.7 years (range 0.3–15.4). Median follow-up time of the cohort after HAART initiation was 8 months (IQR
3.5–13.5). The median change in CD4% from baseline (p < 0.001) was 10.2 (IQR 5.0–13.8) at 6 months (n = 90), and 16.2
(IQR 9.6–20.3) at 12 months (n = 59). Viral loads (VLs) were available for 100 children at 6 months of which 84% had
HIV-1 RNA levels ≤ 50 copies/mL. At 12 months, 80.3% (n = 61) had undetectable VLs. Sixty-five out of 88 children
(73.8%) reported a significant increase (p < 0.001) in weight after the first month. Eighty-nine percent of the cohort (n
= 132) reported ≤ 2 missed doses during any given treatment month (> 95%adherence). Seventeen patients (11.3%) had
a regimen change; two (1.3%) were due to antiretroviral toxicity. The Kaplan-Meier one year survival estimate was 90.9%
(95%confidence interval (CI) 84.8–94.6). Thirteen children died during follow-up (8.6%), one changed service provider,
and no children were lost to follow-up. All 13 deaths occurred in children with advanced HIV disease within 5 months
of treatment initiation. In multivariate analysis of baseline variables against mortality using Cox proportional-hazards
model, chronic gastroenteritis was associated with death [hazard ratio (HR), 12.34; 95%CI, 1.27–119.71) and an HIV-
positive primary caregiver was found to be protective against mortality [HR, 0.12; 95%CI, 0.02–0.88). Age, orphanhood,
baseline CD4%, and hemoglobin were not predicators of mortality in our cohort. Fifty-two percent of the cohort had at
least one HIV-positive primary caregiver, and 38.4% had at least one primary caregiver also on HAART at Sinikithemba
clinic.
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Conclusion: This report suggests that paediatric HAART can be effective despite the challenges of a resource-limited
setting.
Background
In 2005, an estimated 2.3 million children were living
with human immunodeficiency virus/acquired immuno-
deficiency syndrome (HIV/AIDS) worldwide; 700,000
became newly infected, and 570,000 died [1]. Trials in the
United States and Western Europe have demonstrated
that highly active antiretroviral therapy (HAART) is effec-
tive in suppressing HIV viral replication and reversing
immunodeficiency in children [2,3]. The result has been a
reduction in paediatric hospital admissions and a
decrease in morbidity and mortality due to HIV/AIDS [4-
7].
South Africa is home to an estimated 230,000 children
infected with HIV/AIDS [8]. Statistics suggest that 50,000
of these children qualify for HAART by World Health
Organization (WHO) staging, while only 7,000 have been
initiated by the national antiretroviral roll-out program
[8]. Despite this large paediatric HIV population, research
on care and treatment in this setting is limited. Numerous
studies have confirmed the clinical efficacy and feasibility
of HAART in adult HIV patients in Africa [9-13] but to
date very limited experience address the use of paediatric
HAART in Africa. Msellati and colleagues in Côte d'Ivoire,
Mbaye et. al in Senegal, Eley et. al., Cowburn et al, and van
Kooten Niekerk et al., in South Africa, and the AIDS Work-
ing Group of Medecins Sans Frontieres report that good
paediatric outcomes can be achieved in Africa [14-19].
Resource-limited settings pose unique challenges to the
implementation, effectiveness, and sustainability of
HAART programs. Limited availability of paediatric for-
mulations of antiretroviral drugs, weak healthcare infra-
structure and the widespread conviction that paediatric
specialists are needed to initiate and monitor HAART due
to its perceived complexity serve as barriers to comprehen-
sive implementation [20,21]. Threats to effectiveness and
sustainability in the paediatric population include mor-
bidity and mortality of primary caregivers due to rising
HIV prevalence rates, and although the expectation of
poor adherence in this setting leading to widespread
"antiretroviral anarchy" has not been met, treatment fail-
ure and exhaustion of available regimens are ongoing
risks [22].
The present study describes a paediatric HAART cohort in
KwaZulu-Natal, South Africa. We report preliminary out-
comes for 151 children initiated during a 25 month
period.
Methods
Setting
KwaZulu-Natal (KZN), the most populous province in
South Africa, has the highest HIV-1 adult prevalence rate
with the antenatal seroprevalence at 40% [23]. Tuberculo-
sis (TB) incidence in this setting is 782.2 per 100,000, and
two thirds of HIV patients are co-infected with TB[24].
Fifty percent of the paediatric hospital admissions and
40% of the under-five mortalities in KZN are HIV related
[25,26]. Sixty nine percent of children in this province live
in poverty, and more than half the children live in house-
holds with inadequate water supplies and sanitation [27].
McCord Hospital is a state subsidized urban hospital in
Durban, KZN. In 2004, McCord Hospital's Sinikithemba
("We give hope" in IsiZulu) clinic received funding from
the United States' President's Emergency Plan for AIDS
Relief (PEPFAR) fund for HAART scale-up. This funding
subsidizes treatment for all patients. The paediatric co-
payment is ZAR 60/month (~ US$10) and treatment is
free for children whose parents are also receiving HAART
at Sinikithemba. Patient co-pay includes all HAART and
prophylaxis medication, clinic visits, and laboratory test-
ing allowing all patients in the program to receive 6
monthly CD4 and viral load testing.
Sinikithemba clinic has designed and implemented a fam-
ily centered model of care. All adults patients accessing
HAART are routinely interviewed about their children's
health, and those at risk are referred for testing and care.
Reciprocally, some children receiving HAART at Sini-
kithemba have precipitated the diagnosis and subsequent
initiation of treatment for their infected primary caregiv-
ers. Referred family members are prioritized for HAART
enrollment, and families are given clinic appointments
for the same day when possible.
Patient selection, preparation, and follow-up
Clinical and psychosocial selection criteria are identical to
the South African Department of Health guidelines for
care and treatment of HIV-infected children [28]. To qual-
ify for HAART at Sinikithemba paediatric patients must be
symptomatic (WHO clinical stage 3 or 4) or have a CD4%
of < 20% in a child < 18 months of age or a CD4% of <
15% in a child > 18 months of age[29]. In addition there
must be at least one caregiver who is able to supervise the
child's medication and disclosure to another adult living
in the same household. The one requirement unique to
Sinikithemba is the self-reported ability of the primaryBMC Pediatrics 2007, 7:13 http://www.biomedcentral.com/1471-2431/7/13
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caregiver to fund treatment monthly. Patients over the age
of 16 years were referred to Sinikithemba's adult clinic.
In a process modeled after the South African national pro-
gram, patient preparation includes three education ses-
sions for caregivers on HIV, HAART and the importance of
adherence, as well as a thorough clinical assessment of the
child. Baseline laboratory tests include CD4%, full blood
count, liver function tests, urea and electrolytes, and a
chest x-ray and/or ultrasound/sputum (when necessary to
exclude TB). If there are no clinical problems preventing
the initiation of HAART, it is prescribed on the day the car-
egiver finishes the third training session. Antiretroviral
therapy is optimally delayed by 2 months for children
who present with TB at baseline [30]. Children return for
follow-up visits with doctors 2 weeks post HAART initia-
tion and monthly thereafter.
Treatment
The South African National Paediatric Antiretroviral
Guidelines are used[30], though only brand-name medi-
cations are purchased due to PEPFAR's trademark drug
regulations. First line, second line, and TB-concurrent
HAART regimens are summarized in results. (Some chil-
dren had regimens other than the South African national
plan.) All children are prescribed cotrimoxazole prophy-
laxis until their CD4% is consistently > 20% for > 6
months. Ritonavir replaces Kaletra™ for the duration of
concurrent TB treatment in children < 3 years.
Clinical measurements
Weight and height are measured at every clinic visit. Chil-
dren prescribed Kaletra™ also receive a baseline and 6-
monthly fasting cholesterol, glucose, and triglycerides
assay [30,31]. No baseline viral load (VL) is performed
due to cost constraints. CD4% and VL are performed every
6 months in all children. CD4 lymphocyte counts were
performed by flow-cytometry using the FACSCalibur
(Becton Dickinson, San Jose, CA, USA) and VL were deter-
mined with the Amplicor HIV-1 Monitor PCR test v1.5
(Roche Diagnostics Systems, Branchburg, NJ, USA), with
a lower limit of detection of 50 copies of HIV RNA/mL.
Study design and definitions
This was a retrospective cohort study. The study popula-
tion consisted of all paediatric patients who were eligible
for HAART at Sinikithemba from August 31, 2003 until
October 31, 2005. Data were collected from clinical charts
and from the hospital's electronic patient database sys-
tem. Deaths were reported by family members to the
clinic by use of verbal autopsy [32].
Clinical diagnoses of chronic gastroenteritis and TB were
made in accordance with WHO and the South African
Department of Health paediatric clinical guidelines [28-
30]. Pneumocystis carinii pneumonia (PCP) was confirmed
by chest x-ray and/or (when available) sputum induction
for stains to detect Pneumocystis carinii. Lactic acidosis in
our clinic is defined as a lactate of > 5 mmol/l and an arte-
rial blood bicarbonate level of < 20 mmol/L (or a total
venous C02 < 20 mmol/l) with other causes such as sep-
ticeaemia and dehydration excluded [33].
Treatment failure that resulted in a change in regimen was
defined as a VL > 5000 copies of HIV RNA/ml, for greater
than 6 months, resulting in an immunological decline.
Genotypic resistance testing was not available to our pae-
diatric cohort due to cost.
A primary caregiver was recorded as a person who has
consistently assumed responsibility for the housing,
health, or safety of the child [34]. Typically, these were the
individuals who completed pre-HAART training, adminis-
tered medication daily and attended clinic appointments.
There was no requirement that the caregiver be the
patient's only caregiver or that he/she live with the child.
Primary caregivers were designated during a psychosocial
intake interview, and changes were noted by clinicians
during patient visits. One to three primary caregivers were
recorded for each child.
Adherence was assessed by monthly patient self-report of
the primary caregiver and child [35,36]. A treatment inter-
ruption due to poor adherence was defined as three or
more consecutive missed daily doses in a treatment
month.
Lost to follow-up was defined as no communication
between the patient and the clinic staff regarding wherea-
bouts resulting in missing at least 3 monthly follow-up
appointments and/or failure to collect medication[37].
Statistical analysis
Data was analyzed using SAS version 9.1 (SAS Institute
Inc., Cary, NC). Patients lost to follow-up or a change in
service provider was censored at time of event; while all
other patients were censored at time of last clinic visit
through October 31, 2005. Date of death was taken as
endpoint for those patients who died. Changes in median
CD4% were compared by Student's t-test. Weight-for-age
Z-scores (WAZ) and Height-for-age Z-scores (HAZ) over
time were compared using the Kruskall-Wallis test. WAZ
and HAZ scores were calculated by EpiInfo version 3.3.2
based on the Centers for Disease Control (CDC) stand-
ardized weight and height curves. The Cox proportional-
hazards model was used to assess the relationship
between baseline variables and mortality. Variables statis-
tically significant (p < 0.05) in univariate analysis were
subsequently tested in multivariate analysis. Kaplan-
Meier survival methods were used to estimate the proba-BMC Pediatrics 2007, 7:13 http://www.biomedcentral.com/1471-2431/7/13
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bility of survival from the time of initiation of antiretrovi-
ral therapy to death.
Ethics
The research ethics committee of McCord Hospital and
the scientific review committee of CAPRISA, University of
KwaZulu-Natal approved this study.
Sources of Funding
United States' President's Emergency Plan for AIDS Relief
(PEPFAR) fund administered by the Elizabeth Glaser Pae-
diatric AIDS Foundation (EGPAF). PEPFAR funding was
only used for care and treatment of paediatric patients.
PEPFAR and EGPAF did not contribute intellectually
towards this publication.
Results
Study cohort
From August 31, 2003 until October 31, 2005, 151 chil-
dren initiated HAART at Sinikithemba. Thirteen children
died during follow-up (8.6%), one changed service pro-
vider, and no children were lost to follow-up. Median fol-
low-up time of the cohort after HAART initiation was 8
months (IQR 3.5–13.5).
Baseline characteristics (presented in Table 1)
The majority of the cohort had advanced HIV disease at
initiation of treatment as indicated by their WHO clinical
stage, CD4% (n = 146, 5 missing values), and baseline
anthropometry.
Fifty children (33.1%) had TB at baseline: 35 pulmonary,
13 extrapulmonary and two concurrent pulmonary-
extrapulmonary.
At commencement of HAART, 119 children (78.8%) were
antiretroviral naïve, 19 (12.6%) had received HAART pre-
viously at another site, and 13 (8.6%) had a failed preven-
tion of mother-to-child transmission (PMTCT)
intervention.
Initial HAART regimens of the cohort are presented in
Table 2.
Primary Caregivers
The 151 children were cared for by 214 familial and non-
familial primary caregivers as presented in Figure 1. The
distribution of HIV-positive caregivers was not limited to
a few households as 52.3% of children had at least one
HIV-positive caregiver, and 38.4% of children had at least
one primary caregiver also in care at Sinikithemba.
Treatment responses
Immunologic and virologic responses to HAART are pre-
sented in Figure 2. Children that initiated HAART in the 6
months prior data censure did not have a 6-monthly
CD4% and VL result available. All children reaching a 6
month or 12 month endpoint had CD4% and VL. The
cohort's median change in CD4% from baseline was 10.2
(IQR 5.0–13.8) at 6 months (p < 0.001), and 16.2 (IQR
9.6–20.3) at 12 months (p < 0.001). At the time of publi-
cation VLs were available for 100 children at 6 months, of
which 84% (95%CI 80.3–87.7) were undetectable. At 12
months 61 children had available VLs, and 80.3%
(95%CI 75.2–85.4) of these were undetectable. The
cohort's median changes from baseline to last available
WAZ and HAZ scores were 1.0 and 0.4, respectively, after
an average of 8.9 months. The change was statistically sig-
nificant for WAZ (Kruskall-Wallis test p < 0.0001) but not
for the HAZ score (Kruskall-Wallis test p = 0.2880). Sixty-
five out of 88 children (73.8%) reported a significant
increase (p < 0.001) in WAZ score after the first month.
Mortality
In univariate analysis of baseline variables against mortal-
ity, significant hazard ratios were associated with WHO
clinical stage 4, weight-for-age < fifth percentile, and base-
line presence of: TB, chronic gastroenteritis, pneumonia,
and PCP. Loss of one or two parents was not significantly
associated with mortality. In multivariate analysis,
chronic gastroenteritis was significantly associated with
death and the presence of an HIV-positive primary car-
egiver was found to be protective. These data are presented
in Table 3.
The Kaplan Meier (presented in Figure 3) mortality sur-
vival estimate at 12 months was 90.9% (95%CI 84.8–
94.6). Paediatric mortalities are summarized in Table 4.
All 13 deaths occurred within the first 5 months of HAART
initiation. No deaths were attributed to metabolic disor-
ders or other drug-related adverse effects. Autopsy data
were not available, but the most commonly reported
causes of death were chronic gastroenteritis (n = 6) and TB
(n = 4). Other causes of death included: sepsis syndrome
(n = 1), suspected PCP (n = 1), and a respiratory tract
infection (n = 1).
Regimen durability
One hundred and thirty-four patients (88.7%) are still on
their first Sinikithemba HAART regimen. Fifteen (9.9%)
have progressed to a second line, one (0.7%) to a third
line, and one (0.7%) to a fourth line. Of the 17 (11.3%)
that had a regimen change, only two were due to antiret-
roviral toxicity. One child discontinued zidovudine
because of anemia, and one child stopped stavudine
because of lactic acidosis. Seven regimen changes due to
treatment failure were recorded. Initiation or completion
of TB treatment resulted in six children changing regi-
mens. Two children switched from Kaletra™ to Efavirenz
with increasing age (> 3 years).BMC Pediatrics 2007, 7:13 http://www.biomedcentral.com/1471-2431/7/13
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Adherence
Ninety patients (59.6%) reported no missed doses for the
duration of their treatment. Forty-two (27.8%) children
reported "some missed doses" during at least one month
of treatment, not exceeding 2 missed doses per month (>
95% adherence). Sixteen (10.6%) reported one or more
treatment interruptions. Adherence data was missing for 3
children. Common reasons reported for missed doses
were: financial trouble that prevented caregivers from col-
lecting medication on time, vomiting of medication with-
out re-dosing, incorrect dosing by a caregiver, missed
clinic appointments and pharmacy collections, confusion
between multiple caregivers, and child refusal or self-dis-
continuation.
Disclosure
At the time that the data was censored, 12 (7.9%) children
had been made aware of their own HIV+ status: 0% of
children < 3 years of age (n = 0), 2.4% of children 3–5
years (n = 1), 7.5% of children 6–8 years (n = 3), 25% of
children 9–11 years (n = 3) and 83% of children 12–15
years (n = 5). Children who had not been disclosed to
were given partial, inaccurate, or no information by car-
egivers.
Table 1: Baseline characteristics of the Sinikithemba paediatric cohort
Demography [n (%)]
Children 151
Female 77 (51.0%)
Age
< 3 years 39 (25.8%)
3–5 years 43 (28.5%)
6–8 years 43 (28.5%)
≥ 9 years 26 (17.2%)
Median years [range] 5.7 [.3–15.4]
Parent status [n (%)]
Two parents alive 67 (44.4%)
Only father living 19 (12.6%)
Only mother living 27 (17.9%)
Neither parent living 38 (25.1%)
WHO clinical stage [n (%)] [n (%)]
Stage 1 26 (17.2%)
Stage 2 19 (12.6%)
Stage 3 72 (47.7%)
Stage 4 34 (22.5%)
Anthropometry Median (IQR)
Weight-for-age Z-score -1.9 (-3.6 to -0.9)
Height-for-age Z-score -2.2 (-3.0 to -1.1)
CD4 lymphocyte % [n (%)]
< 5% 52 (35.6%)
5%-9% 36 (24.7%)
10%-14% 28 (19.2%)
15%-24% 26 (17.8%)
> 25% 4 (2.7%)
Median CD4% (IQR) 7.4 (2.1–13.7)
Laboratory values Median (IQR)
Albumin (g/L) 30.0 (26.0–35.0)
ALT (IU/L) 18.0 (14.0–28.3)
Hemoglobin (g/dl) 10.1 (8.9–11.0)
Tuberculosis [n (%)]
Present 50 (33.1%)
Other opportunistic infections [n (%)]
Chronic gastroenteritis 52 (34.4%)
Pneumonia 13 (8.6%)
Oesophageal candidiasis 13 (8.6%)
PCP 11 (7.3%)
Cryptococcal meningitis 1 (0.7%)
CMV retinitis 0
Toxoplosmosis 0BMC Pediatrics 2007, 7:13 http://www.biomedcentral.com/1471-2431/7/13
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Discussion
Limitations
The Sinikithemba self-pay requirement may have resulted
in a selection bias towards patients with greater financial
resources. However, their decision to seek semi-private
subsidized care may instead reflect limited access to
HAART in the public sector, where province-wide paediat-
ric enrollment is stunted due to long waiting lists, staff
shortages, laboratory backups, etc. Fifty-six percent of our
cohort is living well below the national poverty line, as
indicated by their eligibility for a government welfare
grant which requires a combined household income of
less than ZAR 800/month (~ US$134). More research is
necessary to understand the financial constraints of this
population, but limited validity of this data due to finan-
cial inequity cannot be assumed.
CD4 and VL laboratory results were available for all chil-
dren who reached a 6 or 12 month endpoint, however no
values were recorded for patients initiated in the 6 months
prior to data censure. The follow-up time of the cohort
was insufficient to confirm the long-term efficacy of
HAART in this setting, although good short-term out-
comes are indicated. To date this paediatric cohort is the
largest in Africa to be documented in the literature; how-
ever, there were relatively few deaths to be included
within the univariate and multivariate analyses.
Analysis
We have documented the initial experiences of 151 paedi-
atric HIV patients initiating HAART in KZN, South Africa.
Our data suggests that a family-centered paediatric
HAART program in a resource-limited setting can be both
clinically effective and sustainable as demonstrated by
therapeutic responses, survival, patient retention, and reg-
imen durability.
The Sinikithemba paediatric cohort's immunologic and
anthropometric responses to HAART were comparable to
the other paediatric cohorts in Africa as well as the United
States and Europe [14-16,38]. Eighty-six out of 90
(95.6%) children at 6 months and 57 out of 59 (96.6%)
children at 12 months had an increase in CD4% from
baseline. In developing-world settings where CD4 moni-
toring is not available due to cost, weight has been used as
a prognostic indicator of clinical effectiveness of HAART
[39,40]. By this measure, the Sinikithemba cohort dem-
onstrated an immediate and significant response to ther-
apy: 65 out of 88 children (73.8%) reported a significant
increase in WAZ score after the first month following
HAART. The significant change in the cohort's WAZ scores
but not HAZ scores is to be expected given the abbreviated
follow-up time of our study [14,41,42].
The Sinikithemba cohort exhibited high degrees of viro-
logic suppression: 84.0% at 6 months and 80.3% at 12
months. In Côte d'Ivoire, 49.3% of children (n = 73)
achieved virologic suppression(< 250 copies/mL) after 12
months [14]. In South Africa, after 12 months of HAART
69.7% of children (n = 264) had a viral load < 400 copies/
ml [43]. In the United States in a multi-site paediatric
cohort of 263 children, Ruthstein et al reported a rate of
34% virologic suppression (< 400 copies/mL) at 12
months[44]. Both the Côte d'Ivoire (mean age: 7.2 yrs, age
range 0.7–15.2 yrs) and the cohort reported by Ruthstein
et. al (mean age: 8.5 yrs, age range 0–17 yrs) had similar
age ranges compared to the Sinikithemba cohort. There
are differences between the Sinikithemba cohort and
other paediatric studies (such as different populations,
viral subtypes, HAART regimens, etc.), which render con-
clusions drawn from direct comparisons to be guarded. It
may also be possible that the Sinikithemba cohort has
higher rates of adherence which may contribute to more
effective virologic suppression [45,46]. More research is
necessary to investigate the sources of this discrepancy.
The Sinikithemba mortality rate of 8.6% compares favora-
bly with other paediatric cohorts in the developing world
(ranges 7.0%-20.0%) [14-16]. Although we have shown
that the baseline presence of many WHO clinical stage 4
Table 2: Initial Antiretroviral Regimens
Age Regimen NRTIs NNRTI/PI
EFV NVP Kaletra™ RTV
< 3 years (n = 39) 1st line d4T/3TC 7 1 23 0
2nd l i n e A Z T / d d I 0000
T B d 4 T / 3 T C 0005
≥ 3 years (n = 112) 1st line d4T/3TC 61 0 1 0
2nd l i n e A Z T / d d I 1010
TB d4T/3TC 37 0 1 2
ARV, antiretroviral therapy
d4T, stavudine; 3TC, lamivdine; AZT, zidovudine;
ddI, didanosine; EFV, efavirenz; RTV, RitonavirBMC Pediatrics 2007, 7:13 http://www.biomedcentral.com/1471-2431/7/13
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symptoms have a higher hazard ratio for mortality; age,
orphanhood, baseline CD4%, and hemoglobin were not
predicators of mortality in our cohort as they were in
other published African cohorts [9-11,47,48].
No children were lost to follow-up, despite much of the
cohort having to contend with long travel distances, mul-
tiple caregivers, and self-funding responsibilities. Ade-
quate follow-up data from other paediatric cohorts is not
available; however, this rate contrasts sharply with data
from African adults cohorts, which have a weighted mean
of 79.8% patient retention at 12 months[12]. There are
several plausible reasons for this. The immediate
improvement in most of the cohort (nearly three-quarters
reporting significant weight gain in the first month) may
have convinced caregivers of the effectiveness of HAART
and the need for ongoing care. Finally, treating caregivers
and children at the same site may create stronger ties to
families resulting in better retention.
Harries et al. summarize the clinical arguments against the
sustainability of HAART by advising HAART programs in
HIV status and HAART in the primary caregivers of the Sinikithemba paediatric cohort Figure 1
HIV status and HAART in the primary caregivers of the Sinikithemba paediatric cohor: The Sinikithemba cohort 
was cared for by 214 familial and non-familial primary caregivers. Of these 214 primary caregivers; 105 (49.1%) had tested pos-
itive for HIV of whom 68 (64.8%) were also receiving HAART at Sinikithemba, 86 (40.2%) were unaware of their status, and 23 
(10.7%) had tested HIV negative. Ten children were in institutional care (orphanage), no primary caregiver identified.
21%
32%
9%
25%
50%
62%
27%
12%
25%
5%
16%
9%
18%
25%
33%
12%
82%
32%
61%
50%
25%
67%
2% 0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
      Mother     
(n=81)
Grandparent
(n=45)
      Father      
(n=44)
Aunt/Uncle (n=33)       Sibiling      
(n=4)
Step-parent (n=4) Adoptive parent
(n=3)
HIV+, not in care at Sinikithemba Clinic 
HIV+, in care at Sinikithemba Clinic 
HIV–
HIV status unknown/untestedBMC Pediatrics 2007, 7:13 http://www.biomedcentral.com/1471-2431/7/13
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resource-limited areas that they would be "prudent to
decide what drugs might be used for salvage antiretroviral
therapy when (author's emphasis) drug resistance, side-
effects, or both become a problem."[22] However, only
two children at Sinikithemba (1.3%) experienced an
adverse event that required a regimen change, a rate simi-
CD4% and Viral Loads changes of the Sinikithemba paediatric cohort in response to HAART Figure 2
CD4% and Viral Loads changes of the Sinikithemba paediatric cohort in response to HAART: A. Median increase 
in CD4% from baseline. The vertical bars in subfigure A indicate IQR. B. Percentage of cohort achieving undetectable viral 
loads. The vertical bars in subfigure B indicate 95% CI.
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lar to paediatric results from Côte d'Ivoire and substan-
tially lower than the percentages recorded for African
adult cohorts (range 14.3%-80.2%) [12,14]. We have not
conducted structured adherence analysis, but patient self-
report data, high rates of viral suppression, and low inci-
dence of treatment failure indicate that adherence levels
were not a threat to regimen durability or an obstacle to
good clinical outcomes in this cohort [45].
Other paediatric HAART studies in Africa have analyzed
the rates of orphanhood within their cohorts, but to our
knowledge none have recorded the HIV-status of the pri-
mary caregivers or analyzed the outcomes associated with
HIV-positive caregivers [34]. Our data shows that
although more than half of the Sinikithemba cohort is
cared for by at least one HIV-positive caregiver, these car-
egivers showed a protective effect against mortality when
compared with caregivers who were untested or HIV neg-
Table 3: Mortality: Cox proportional hazards models between baseline characteristics and death
Univariate analysis Multivariate analysis
Baseline Characteristic No. of Deaths Hazard ratio 95% CI p Hazard ratio 95% CI p
Gender
Male 6 1.00 1.00 -
Female 7 1.14 (0.38–3.40) 0.810 2.78 (0.66–11.86) 0.163
Age
< 3 yrs 5 1.00 1.00 -
3–5 yrs 2 0.35 (0.07–1.81) 0.210 1.37 (0.21–9.04) 0.747
6–8 yrs 3 0.52 (0.12–2.16) 0.365 0.25 (0.02–2.93) 0.268
≥ 9 yrs 3 0.92 (0.22–3.85) 0.908 2.18 (0.44–10.85) 0.342
WHO clinical stage
Stage 1–3 7 1.00 1.00 -
Stage 4 6 3.01 (1.01–8.95) 0.048* 1.82 (0.41–8.03) 0.430
Weight (**2 missing values)
≥ 5 Percentile 1 1.00 1.00 -
< 5 Percentile 10 8.60 (1.10–67.15) 0.040* 4.96 (0.45–55.31) 0.193
CD4% (**1 missing value)
≥ 5% 5 1.00 - -
< 5% 7 2.65 (0.84–8.34) 0.097 - -
Tuberculosis
Absent 5 1.00 1.00 -
Present 8 3.39 (1.11–10.37) 0.032* 1.08 (0.25–4.59) 0.919
Pulmonary
Absent 9 1.00 --
Present 4 1.53 (0.47–5.01) 0.480 --
Extrapulmonary
Absent 10 1.00 --
Present 3 3.06 (0.84–11.20) 0.091 --
Chronic gastroenteritis
Absent 3 1.00 1.00 -
Present 10 6.69 (1.84–24.30) 0.004* 12.34 (1.27–119.71) 0.030*
Pneumonia
Absent 9 1.00 1.00 -
Present 4 5.23 (1.61–16.98) 0.006* 4.03 (0.79–20.54) 0.094
PCP
Absent 10 1.00 1.00 -
Present 3 3.81(1.05–13.86) 0.042* 5.35 (0.84–33.86) 0.075
Oesophageal candidiasis
Absent 12 1.00 - -
Present 1 0.92 (0.12–7.04) 0.932 - -
Hemoglobin
> 10 g/dl 5 1.00 - -
≤ 10 g/dl 8 1.87 (0.61–5.73) 0.272 - -
Primary caregiver HIV Status
HIV negative or unknown 10 1.00 - 1.00 -
HIV positive 3 0.26 (0.07–0.95) 0.041* 0.12 (0.02–0.88) 0.037*
Primary caregiver receiving HAART at Sinikithemba
Primary caregiver not in care 12 1.00 - - -
Primary caregiver in care 1 0.13 (0.02–1.01) 0.051 - -
Parent status
Two parent alive 6 1.00 - - -
One parent alive 4 0.92 (0.26–3.26) 0.896 - -
Neither parent living 3 0.82 (0.21–3.28) 0.778 - -BMC Pediatrics 2007, 7:13 http://www.biomedcentral.com/1471-2431/7/13
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ative. We hypothesize that HIV-positive primary caregiv-
ers on HAART at the same site may be able to provide
more informed treatment support for their children
resulting in better outcomes. Those HIV positive caregiv-
ers not yet on HAART may still be more knowledgeable
about symptom management and disease progression,
more experienced with health care systems and/or more
likely to access available health services. Further research
is necessary to investigate these possibilities, but the
necessity of supporting all caregiver/dependent relation-
ships is clear.
Conclusion
Many settings in Africa, with social and economic con-
straints placed on children, demand thoughtful and sensi-
tive management of HIV-positive children on HAART.
Despite this, we have shown that a cohort with advanced
HIV disease in this setting responds favorably to treat-
ment.
All 13 deaths occurred in children with advanced HIV dis-
ease within 5 months of treatment initiation. This sug-
gests that a greater effort should be made to identify and
treat HIV-positive children at an earlier stage of their infec-
tion, and that children with advanced disease should be
closely monitored and supported at the onset of HAART.
Based on these data we suggest that these children, espe-
cially those who present with chronic gastroenteritis
which may interfere with uptake/absorption of the medi-
cations, be referred to paediatric inpatient wards or a local
palliative (step-down) care center for HAART initiation.
Treatment counselors can conduct home visits to monitor
and support caregivers, especially those with little treat-
ment experience.
A third of our cohort presented with TB at baseline and
four deaths were TB related. With such a high prevalence
in this setting, more research on paediatric HIV/TB co-
infection is necessary, especially with regard to immune
reconstitution syndrome, multi-drug resistance, and best-
practice guidelines for concurrent and/or sequential
HAART/TB treatment in order to minimize drug toxicity
and optimize outcomes [9,24].
The high rate of HIV positive caregivers indicates that it is
imperative to transform the paediatric treatment model
Kaplan-Meier mortality survival curve of the cohort Figure 3
Kaplan-Meier mortality survival curve of the cohort.
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from child-centered to family-centered in order to protect
the integrity of caregiving structures and prevent the neg-
ative paediatric outcomes associated with the declining
health or death of a primary caregiver [48]. Recruiting
untested caregivers for testing and extending treatment
opportunities to the caregivers who test positive is a nec-
essary step towards protecting the future health and well-
being of the paediatric patient.
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